Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 143 No. 4344 (2013)

Changes in renal function over time in patients with cardiac resynchronisation therapy

  • Beat Schaer
  • Lara Hitz
  • Christian Sticherling
  • Mischa S Kühne
  • Michael Dickenmann
  • Luc Jordaens
  • Stefan Osswald
  • Dominic A Theuns
Cite this as:
Swiss Med Wkly. 2013;143:w13863


  1. Cleland JCF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
  2. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
  3. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. for the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) Investigators Cardiac-Resynchronization therapy for mild-to-moderate heart failure N Engl J Med. 2010;363:2385–95.
  4. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. for the MADIT-CRT Trial Investigators Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events N Engl J Med. 2009;361:1329–38.
  5. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, et al. Committee for Practice Guidelines of the European 2010 Focused Update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail. 2010;11:1143–53.
  6. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Gattis Stough W, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol. 2010;105:1140–6.
  7. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85–97.
  8. DA Theuns, BA Schaer, OII Soliman, D Altmann, C Sticherling, ML Geleijnse, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011;13:62–9.
  9. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.
  10. Goldenberg I, Moss AJ, McNitt S, Barsheshet A, Gray D, Andrews ML, et al. Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Heart Rhythm. 2010;7:1777–82.
  11. Boerrigter G, Costello-Boerrigter LC, Abraham WT, St. John Sutton MG, Heublein DM, Kruger KM, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail. 2008;14:539–46.
  12. Damman K, Navis G, Smilde TDJ, Voors AA, van der Bij W, van Veldhuisen DJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9:872–8.
  13. Fung JWH, Szeto CC, Chan JYS, Zhang Q, Chan HCK, Yip GWK, et al. Prognostic value of renal function in patients with cardiac resynchronization therapy. Int J Cardiol. 2007;122:10–6.
  14. by Stephen Z. Fadem, M.D., FACP, FASN and Brian Rosenthal, last accessed 16th of November 2011
  15. Levey AS, Bosch JP, Breyer Lewis J, Greene T, Rogers N, Roth D for the Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
  16. Frank M, Guarino-Gubler S, Burnier M, Maillard M, Keller F, Gabutti L. Estimation of glomerular filtration rate in hospitalised patients: are we overestimating renal function? Swiss Med Wkly. 201219;142:w13708. doi: 10.4414/smw.2012.13708.
  17. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.
  18. Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardioverter defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006;98:485–90.
  19. Adelstein EC, Shalaby A, Saba S Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol. 2010;33:850–9.
  20. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. for the MADIT-II Investigators Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96.
  21. Van Bommel RJ, Mollema SA, Borleffs CJ, Bertini M, Ypenburg C, Marsan NA, et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol. 2011;57:549–55.
  22. Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J. 2011;32:184–90.

Most read articles by the same author(s)

1 2 3 4 > >>